Acrivon Therapeutics Common Stock Statistics
Share Statistics
Acrivon Therapeutics Common Stock has 31.14M shares outstanding. The number of shares has increased by 40.29% in one year.
| Shares Outstanding | 31.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.96M |
| Failed to Deliver (FTD) Shares | 182 |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 1.08M, so 3.47% of the outstanding shares have been sold short.
| Short Interest | 1.08M |
| Short % of Shares Out | 3.47% |
| Short % of Float | 4.91% |
| Short Ratio (days to cover) | 15.38 |
Valuation Ratios
The PE ratio is -1.8 and the forward PE ratio is -3.11.
| PE Ratio | -1.8 |
| Forward PE | -3.11 |
| PS Ratio | 0 |
| Forward PS | 8.6 |
| PB Ratio | 0.9 |
| P/FCF Ratio | -2.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acrivon Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.75, with a Debt / Equity ratio of 0.
| Current Ratio | 9.75 |
| Quick Ratio | 9.75 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -53.43%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -53.43% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.04M |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 24.55% in the last 52 weeks. The beta is 1.7, so Acrivon Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 1.7 |
| 52-Week Price Change | 24.55% |
| 50-Day Moving Average | 6.93 |
| 200-Day Moving Average | 7.66 |
| Relative Strength Index (RSI) | 39.46 |
| Average Volume (20 Days) | 53.11K |
Income Statement
| Revenue | n/a |
| Gross Profit | -536.00K |
| Operating Income | -67.24M |
| Net Income | -60.39M |
| EBITDA | -59.85M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.74 |
Balance Sheet
The company has 36.02M in cash and 4.64M in debt, giving a net cash position of 31.37M.
| Cash & Cash Equivalents | 36.02M |
| Total Debt | 4.64M |
| Net Cash | 31.37M |
| Retained Earnings | -116.42M |
| Total Assets | 214.68M |
| Working Capital | 174.16M |
Cash Flow
In the last 12 months, operating cash flow was -42.64M and capital expenditures -1.29M, giving a free cash flow of -43.93M.
| Operating Cash Flow | -42.64M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -43.93M |
| FCF Per Share | -1.99 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.55% |
| FCF Yield | -25.51% |
Analyst Forecast
The average price target for ACRV is $22, which is 297.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 297.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 5.61 |
| Piotroski F-Score | 2 |